News Headlines

  1. Ennolys By Lesaffre Is Expanding Its Contract Manufacturing Services To Accelerate And Mitigate The Risks Associated With The Industrialization Of Sustainable Innovations 8/27/2026

    Ennolys, the Lesaffre subsidiary specializing in biotechnology and process industrialization, is launching an expanded range of CDMO¹ services focused on fermentation, DSP (Downstream Processing), and drying.

  2. Celularity And MuseCell Innovations Announce U.S. Manufacturing Collaboration For The Dezawa MuseCell Platform 8/27/2026

    Celularity Inc. (“Celularity”), a longevity-focused regenerative and cellular medicine company, and MuseCell Innovations Pte. Ltd. (“MCI”), the owner of the Dezawa MuseCell platform, today announced an additional U.S.-based manufacturing collaboration under which Celularity will undertake activities to establish U.S. production of Dezawa MuseCells (“DMCs”) at Celularity’s Florham Park, New Jersey facility.

  3. Osivax And GC Biopharma Enter Strategic Collaboration To Develop A Next-Generation Influenza Vaccine Combining OVX836 And GC FLU 8/27/2026

    Osivax, a clinical-stage biopharmaceutical company developing differentiated influenza vaccines designed to generate broad-spectrum immune responses, and GC Biopharma, a leading South Korean biopharmaceutical company with extensive experience in vaccines and plasma-derived products, today announced a long-term collaboration to develop and commercialize a next-generation seasonal influenza vaccine candidate designed to provide broader and more durable protection against a wide range of influenza strains.

  4. 4basebio And Genezen Enter Into Strategic Collaboration To Advance Synthetic, Cell-Free DNA Platforms For Next-Generation Viral Vector Manufacturing 8/26/2026

    4basebio PLC (AIM: 4BB), a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), today announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA® development and clinical programs.

  5. Biohaven And SK Biopharmaceuticals Enter Into Strategic Global Licensing Agreement For Novel Kv7 Ion Channel Platform And Opakalim, Lead Candidate For Epilepsy 8/26/2026

    Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and SK Biopharmaceuticals Co., Ltd. ("SK Biopharmaceuticals") today announced a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy, with RISE3 trial topline results expected in 2H 2026.

  6. Cambrex High Point Completes FDA, PMDA And TGA PreApproval Inspections, Advancing Commercial Manufacturing Capabilities 8/25/2026

    Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced the successful completion of three Pre-Approval Inspections (PAIs) at its High Point, North Carolina facility by the U.S. Food and Drug Administration (FDA), Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and Australia's Therapeutic Goods Administration (TGA). The completion of all three inspections enables High Point to manufacture approved active pharmaceutical ingredients (APIs) for the United States, Japan, and Australia, establishing the facility as the newest commercial manufacturing site within the Cambrex global network.

  7. Hovione Completes €40M Expansion Of Loures Tablet Manufacturing Center Adding Commercial-Scale Batch Tableting Capacity 8/25/2026

    Hovione, a globally-integrated specialist pharmaceutical CDMO, has completed expansion of the company’s tablet development and manufacturing center at its main global campus in Loures, Portugal adding 25 percent more commercial-scale batch tableting capacity for the integrated supply of oral solid dosage products.

  8. Aurigene Pharmaceutical Services Enters Into Long-Term Manufacturing And Supply Partnership With A Leading Global Pharmaceutical Company 8/25/2026

    Aurigene Pharmaceutical Services Limited (“Aurigene”), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd., today announced a strategic, long-term Manufacturing and Supply Agreement (MSA) with a leading global pharmaceutical company for the commercial drug-product manufacturing and supply of a diversified portfolio for USA, Europe, Canada and Emerging markets.

  9. Lundbeck And EVERSANA Announce Strategic Partnership To Advance AI-Powered Commercialization 8/25/2026

    Lundbeck, a global pharmaceutical company focused exclusively on brain health, and EVERSANA®, a leading global provider of commercial services to the life sciences industry, today announced a strategic partnership to advance AI-powered commercialization across Lundbeck's U.S. commercial organization.

  10. Ashland Advances High-Growth Oral Biologics Delivery Applications With Launch Of Permexa&trade Sodium Caprate 8/24/2026

    Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.